Arvinas Stock
Arvinas, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Randy Teel
- Employees
- 246
- Market cap
- $450 M
- IPO
- 27/09/2018
Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting…
Arvinas stock: price history
1D
-2.7%
1W
-8.8%
1M
-14.6%
6M
-36.6%
YTD
-41.2%
1Y
-28.0%
2Y
-74.9%
5Y
-91.8%
10Y
–
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~6% stronger price swings than usual
Ask the agents about Arvinas
Analyst assessment of Arvinas
PRICE TARGET LOW
US$10.00
CONSENSUS
US$14.17
MEDIAN
US$13.00
PRICE TARGET HIGH
US$20.00
0
STRONG BUY
19
BUY
6
HOLD
1
SELL
0
STRONG SELL
26
TOTAL · Buy
As of: 10/08/2026
Arvinas stock metrics
P/E
36.68
P/B
0.8
EV/EBITDA
93.23
RETURN ON EQUITY
30.1%
NET MARGIN
67.8%
DEBT/EQUITY
0.01
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
88.1%
FLOAT SHARES
56,812,754
AVG. DAILY VOLUME (30D)
831,409
Insider transactions (SEC)
Bain Linda
Cunningham Everett
Kennedy Edward Moore Jr.
Morrison Briggs
Norwalk Leslie V
Institutional holders
Comparable stocks
Frequently asked questions about Arvinas stock
What does Arvinas do?
Arvinas, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Randy Teel, the company employs around 246 people.
The IPO was on 27/09/2018; the stock trades on NASDAQ under the ticker ARVN.
What do analysts say about Arvinas stock?
26 analysts rate the stock, the consensus is Buy (as of 10/08/2026).
The average price target is US$14.17, ranging from US$10.00 to US$20.00, with a median of US$13.00.
This is an external assessment, not a statement by Market Jury.
When does Arvinas report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly 6% stronger than usual.
Does Arvinas pay a dividend?
No, Arvinas currently does not pay a dividend.
Which stocks are comparable to Arvinas?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Arvinas stock analyzed?
Clicking "Analyze stock" lets five strategies assess Arvinas against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.